padeliporfin VTP

Phase 3Small molecule

padeliporfin VTP is one of 12 small molecule programs targeting Transitional Cell Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Transitional Cell CarcinomaActive, not recruiting

Transitional Cell CarcinomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Transitional Cell Carcinoma

#DrugCompanyPhaseTrials

Taxol

Eloxatin

Mitosol

Ifex

BBaxter Healthcare Corporation

Adrucil

Opdivo

3 7

Dato-Dxd

AstraZeneca

Phase 3

1 8

Rilvegostomig

AstraZeneca

Phase 3

1 9

padeliporfin VTP

SSteba Biotech S.A.

Phase 3

1 10

Tecentriq

Roche

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Active, not recruiting

Transitional Cell Carcinoma

NCT04620239

Clinical

Trials by Indication[1]

Transitional Cell Carcinoma1 trial

Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (Padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer

Active, not recruiting·SSteba Biotech S.A.·Phase 3·NCT04620239·89 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for padeliporfin VTP. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — padeliporfin VTP compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for padeliporfin VTP. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Steba Biotech S.A. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSteba Biotech S.A.

padeliporfin VTP

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Transitional Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News